Susan L. Kelley - 18 Jan 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role: Director
Signature: /s/ Thomas P. Kelly, Attorney-in-Fact
Issuer symbol: DCPH
Transactions as of: 18 Jan 2022
Net transactions value: +$49,955
Form type: 4
Filing time: 20 Jan 2022, 16:01:11 UTC
Previous filing: 24 Jun 2021
Next filing: 10 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DCPH	Stock Option (Right to Buy)	Award	$49,955	+9,570		$5.22	9,570	18 Jan 2022	Common Stock	9,570	$8.27	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022.

Content

These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022.